SynthesisBMC urology2018
Antihypertensive drugs use and the risk of prostate cancer: a meta-analysis of 21 observational studies.
Synthesis in BMC urology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 4 syntheses or guidelines pooled it, 59 citations in OpenAlex.
- Epidemiology of prostate cancer in Nigeria: a mixed methods systematic review.Cancer causes & control : CCC · 2025Pooled it
- Pooled it
- Risk factors for prostate cancer: An umbrella review of prospective observational studies and mendelian randomization analyses.PLoS medicine · 2024Pooled it
- 2022 Update on Prostate Cancer Epidemiology and Risk Factors-A Systematic Review.European urology · 2023Pooled it
- Cancer and Hypertension: Shared Mechanisms, Treatment Interactions, and Clinical Management.Cancer medicine · 2026Review
- Neurobiology of urological diseases.Current urology · 2026Review
- Impact of Antihypertensive and Lipid-Lowering Agents on Hepatocellular Carcinoma Risk in Patients with Fatty Liver Disease and Diabetes.Digestive diseases and sciences · 2025Article
- Blood Pressure, Hypertension, and Antihypertensive Medication Use and Risk of Total and Fatal Prostate Cancer in Black and White Men in the Atherosclerosis Risk in Communities (ARIC) Study.Journal of racial and ethnic health disparities · 2025Article
- The Crosstalk between Nerves and Cancer-A Poorly Understood Phenomenon and New Possibilities.Cancers · 2024Review
- Heart failure pharmacotherapy and cancer: pathways and pre-clinical/clinical evidence.European heart journal · 2024Review
- Several first-line anti-hypertensives act on fibrosarcoma progression and PD1ab blockade therapy.Journal of orthopaedic surgery and research · 2024Article
- Genetic proxies for calcium channel blockers and cancer: a Mendelian randomization study.Journal of human hypertension · 2023Article
- Use of calcium channel blockers does not increase breast cancer risk: findings from a nationwide population-based cohort study in Taiwan.Hypertension research : official journal of the Japanese Society of Hypertension · 2023Article
- Blood pressure, calcium channel blockers, and the risk of prostate cancer: a Mendelian randomization study.Cancer causes & control : CCC · 2023Article
- CACNA1D overexpression and voltage-gated calcium channels in prostate cancer during androgen deprivation.Scientific reports · 2023Article
- Cardiovascular Disease as a Consequence or a Cause of Cancer: Potential Role of Extracellular Vesicles.Biomolecules · 2023Review
- Association between antihypertensive drugs and oral cancer: a drug target Mendelian randomization study.Frontiers in pharmacology · 2023Article
- Antihypertensive Therapy and Incidence of Cancer.Journal of clinical medicine · 2022Article
- Renin-Angiotensin-Aldosterone System Inhibitors and Risk of Cancer: A Population-Based Cohort Study Using a Common Data Model.Diagnostics (Basel, Switzerland) · 2022Article
- Antihypertensive treatment and risk of cancer: an individual participant data meta-analysis.The Lancet. Oncology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDue to the lack of strong evidence to identify the relationship between antihypertensive drugs use and the risk of prostate cancer, it was needed to do a systematic review to go into the subject.
methodsWe systematically searched PubMed, Web of Science and Embase to identify studies published, through May 2015. Two evaluators independently reviewed and selected articles involving the subject. We used the Newcastle-Ottawa Scale (NOS) to assess the quality of the studies. All extracted results to evaluate the relationship between antihypertensive drugs usage and prostate cancer risk were pool-analysed using Stata 12.0 software.
resultsA total of 12 cohort and 9 case-control studies were ultimately included in our review. Most of the studies were evaluated to be of high quality. There was no significant relationship between angiotensin converting enzyme inhibitors (ACEI) usage and the risk of prostate cancer (RR 1.07, 95% CI 0.96-1.20), according to the total pool-analysed. Use of angiotensin receptor blocker (ARB) was not associated with the risk of prostate cancer (RR 1.09, 95% CI 0.97-1.21), while use of CCB may well increase prostate cancer risk based on the total pool-analysed (RR 1.08, 95% CI 1-1.16). Moreover, subgroup analysis suggested that use of CCB clearly increased prostate cancer risk (RR 1.10, 95% CI 1.04-1.16) in terms of case-control studies. There was also no significant relationship between use of diuretic (RR 1.09, 95% CI 0.95-1.25) or antiadrenergic agents (RR 1.22, 95% CI 0.76-1.96) and prostate cancer risk.
conclusionsThere is no significant relationship between the use of antihypertensive drugs (ACEI, ARB, beta-blockers and diuretics) and prostate cancer risk, but CCB may well increase prostate cancer risk, according to existing observational studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.